تحميل...
Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong
BACKGROUND: Pembrolizumab has been shown to improve overall survival (OS) and progression free survival (PFS) compared to ipilimumab in patients with ipilimumab-naïve advanced melanoma; however, there are no published data on the cost-effectiveness for pembrolizumab compared to standard-of-care trea...
محفوظ في:
| الحاوية / القاعدة: | Cost Eff Resour Alloc |
|---|---|
| المؤلفون الرئيسيون: | , , , , , , , |
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
BioMed Central
2020
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6964068/ https://ncbi.nlm.nih.gov/pubmed/31969794 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12962-020-0200-9 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|